ClinicalTrials.gg
RecruitingNCT06496256Updated Sep 28, 2026

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

An interventional study of Barrigel and Transrectal Ultrasound in Prostate Cancer, sponsored by Palette Life Sciences, Inc.. Recruiting at 13 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Palette Life Sciences, Inc. · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Sep 28, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
1,033rd of 3,023
84 · median 48
Started
2024
with 174 others
No phase
764 of 3,596
157 open now
Primary completion
2028-12
later than 748 of 971 live
Registered
3,223rd of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,033rd largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 175 that started in 2024, is one of 764 with no phase, reaches primary completion later than 748 of the 971 other live ones, and was the 3,223rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.

Read the detailed description

Barrigel is composed of biodegradable material and maintains space for the entire course of prostate or prostate bed radiotherapy and is intended to be absorbed by the patient's body over time.

To evaluate the safety and effectiveness of Barrigel to reduce the radiation dose delivered to the anterior rectum by creating a space when injected between the rectum and the prostate bed in men receiving definitive external beam radiation therapy (intensity-modulated radiation therapy) for recurrence of prostate cancer after radical prostatectomy.

A prospective, randomized, controlled, single-masked multicenter study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. (ECOG) performance status of 0 or 1
  3. Prostatectomy surgeon notes specifying successful bilateral nerve Sparing procedure
  4. Documentation of an intra or interfascial radical prostatectomy
  5. Confirmed diagnosis of adenocarcinoma of the prostate treated primarily with radical prostatectomy with pN0 or pNX pathologic stage
  6. No radiographic evidence of local, regional, or distant disease via PSMA PET or Axumin fluciclovine F18 scan
  7. Prostate specific antigen (PSA) 0.1 ng/mL or higher
  8. Intent to receive definitive radiation therapy to the prostate bed
  9. Written for study participation prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to hyaluronic acid
  2. Pathologic T4 disease
  3. Prior local prostate cancer therapy including cryotherapy or brachytherapy.
  4. Prior post-prostatectomy or pelvic radiation therapy
  5. Planned elective pelvic lymph node radiation therapy
  6. Prior anorectal surgery (e.g. low anterior resection, abdominoperineal resection, absence of a rectum)
  7. Inflammatory bowel disease requiring treatment with (e.g. Crohn's disease, ulcerative colitis)
  8. Active connective tissue disorder including lupus or scleroderma
  9. Any urogenital abnormality that could limit the ability to access the Barrigel injection site
  10. White blood cell count \<4000/uL or >12,000/uL.
  11. \<10 g/dL (transfusion or other intervention to achieve this is acceptable).
  12. Active bleeding disorder or coagulopathy defined as >35 seconds or INR >1.4 or count \<100,000/mm3.
  13. Serum /ALT >2.5 times the institutional
  14. Creatinine >2.0 mg/dL
  15. >2.0 mg/dL
  16. History of chronic renal failure.
  17. History of uncontrolled diabetes (e.g. symptomatic hyperglycemia that is not controlled with medical management; fasting blood glucose >300 mg/dL).
  18. History of acquired immunodeficiency syndrome (AIDS). Patients with controlled infection ( ≥ 350 cells/µL) and no history of AIDS-defining opportunistic infections may be included.
  19. to having an MRI or PSMA/PET scan (e.g. non-MRI compatible device).
  20. Presence of bilateral hip implants, although unilateral hip implant may be permissible if the implant is MRI compatible and does not produce artifact that interferes with any requirements of the study protocol
  21. Subject unable or unwilling to comply with study requirements
  22. Any condition that in the investigator's opinion would prevent administration or completion of study therapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Treatment Arms

    Subjects will be injected Barrigel between the rectum and prostate bed using transrectal ultrasound for guidance.

    Device: Barrigel · Device: Transrectal Ultrasound

  • Sham comparator
    Control Arm

    Subjects randomized to the control group will not receive Barrigel but will have a Transrectal ultrasound probe inserted to simulate that aspect of the injection of Barrigel.

    Device: Transrectal Ultrasound

Interventions

  • DeviceBarrigel

    Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space

  • DeviceTransrectal Ultrasound

    All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle

06

What researchers measure

Primary outcomes

  1. Reduction in volume of rectum receiving radiation dose

    Investigational subjects only: Achievement of a ≥ 25% change in reduction in the volume of rectum receiving 90% of the prescription dose in 70% of the subjects.

    Time frame: 3 months

Secondary outcomes

  1. Grade 2 Toxicities

    Test whether the use of the Barrigel spacer does not increase the incidence of acute grade 2+ GI toxicity within the first 3 months, which will be assessed using the proportion of subjects who have one or more incidences of acute grade 2+ GI toxicity within the first 3 months.

    Time frame: 3 Months

  2. Expanded Prostate Cancer Index Composite (EPIC) bowel QOL

    Evaluate the change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment composite score (from baseline within 3 months after completion of radiation therapy. The EPIC is graded on a 12 point scale, with a higher score indicating a higher outcome.

    Time frame: 3 months

  3. Expanded Prostate Cancer Index Composite (EPIC) Urinary QOL

    Evaluate the change in Expanded Prostate Cancer Index Composite (EPIC) Urinary Assessment composite score from baseline within 3 months after completion of radiation therapy. The EPIC is graded on a 12 point scale, with a higher score indicating a higher outcome.

    Time frame: 3 months

Other outcomes

  1. Adverse Events

    All adverse events

    Time frame: 3 months

07

Study locations

8 of 13 sites recruiting
  • Arizona Clinical Trial
    Chandler, Arizona 85225, United States
    Active, not recruiting

    Not enrolling at this site.

  • Sansum Clinic-Sutter Health
    Santa Barbara, California 93105, United States
    Active, not recruiting

    Not enrolling at this site.

  • Baptist Health South Florida Inc
    Boca Raton, Florida 33486, United States
    Recruiting
  • Augusta University Research Institute
    Augusta, Georgia 30912, United States
    Recruiting
    • Candelario Laserna, MD · Contactcalaserna@augusta.edu · 706-721-9680
    • Zachary Klaassen, MD · Principal investigator
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Summit Health
    Clifton, New Jersey 07013, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
  • Thomas Jefferson Health Sidney Kimmel Cancer Center
    Philadelphia, Pennsylvania 19107, United States
    Active, not recruiting

    Not enrolling at this site.

  • Urology Austin
    Austin, Texas 78745, United States
    Recruiting
  • Houston Metro Urology
    Houston, Texas 77027, United States
    Withdrawn

    Not enrolling at this site.

  • Virginia Urology Center
    Richmond, Virginia 23235, United States
    Recruiting
    • Jordan Moore · Contactjnmoore@uro.com · 804-288-2785
    • J Daniel Pennington, MD · Principal investigator
  • St. Vincent Hospital
    Fitzroy, Victoria 3065, Australia
    Not yet recruiting
  • GenesisCare Ringwood
    Melbourne, Victoria 3002, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be submitted to FDA as part of a 510(k). Study data will be shared with other researchers for analysis and reporting after FDA clearance, including protocol, SAP, CSR, and raw data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Within three months of the FDA decision.

Access criteria: Qualified researchers with the intent to publish their results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2028, 49 months after the start.

Of 57 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 49 months is close to that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Dec 2027 → Dec 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Dec 1, 2028was Dec 2027
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added. Houston Metro Urology is now Withdrawn
Show 8 added (7 United States, 1 Australia)
  • Arizona Clinical Trial · Chandler, United States
  • Sansum Clinic-Sutter Health · Santa Barbara, United States
  • Baptist Health South Florida Inc · Boca Raton, United States
  • Augusta University Research Institute · Augusta, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • Thomas Jefferson Health Sidney Kimmel Cancer Center · Philadelphia, United States
  • Virginia Urology Center · Richmond, United States
  • St. Vincent Hospital · Fitzroy, Australia
Sep 28, 2026
Primary completion
Dec 1, 2027→Dec 1, 2028
Sep 28, 2026
Study completion
Dec 31, 2027→Dec 31, 2028
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    8 sites added. Houston Metro Urology is now Withdrawn
    Show 8 added (7 United States, 1 Australia)
    • Arizona Clinical Trial · Chandler, United States
    • Sansum Clinic-Sutter Health · Santa Barbara, United States
    • Baptist Health South Florida Inc · Boca Raton, United States
    • Augusta University Research Institute · Augusta, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • Thomas Jefferson Health Sidney Kimmel Cancer Center · Philadelphia, United States
    • Virginia Urology Center · Richmond, United States
    • St. Vincent Hospital · Fitzroy, Australia
    Primary completion Dec 1, 2027→Dec 1, 2028
    Study completion Dec 31, 2027→Dec 31, 2028
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06496256
Lead sponsor
Palette Life Sciences, Inc.
Collaborators
Teleflex
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Oct 31, 2024
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Joseph Onokwai, MD, MPH, PhD
Contact
v-jonokwai@palettelifesciences.com
7738864397
Cliff Kline
Contact
cliff.kline@teleflex.com
8054569653

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion